Alle afleveringen
283 afleveringen, van nieuw naar oud
-
Alex Blyth - CEO LifT Biosciences at BIO Boston 2025
22 juli 2025 · 16 min
From BIO Boston: Alex Blyth, CEO of LifT Biosciences Lees meer
In this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game.
We talk about:
Why targeted therapies are failing most patients
What tumour escape is and why it’s the real enemy
How LiFt’s “super neutrophils” could be the Keytruda of innate immunity
And the personal loss that pushed Alex to rethink everything we know about cancer treatment
Alex’s story is sharp, ambitious, and deeply personal — exactly the kind of leadership biotech needs right now.
This is the first in a series of in-person interviews from BIO Boston with some of the sharpest founders and execs in the industry.
Stay tuned — more to come.
-
Episode 57– Jaideep Dudani - CEO Ouro Medicines
22 juli 2025 · 24 min
Welcome to another episode of The Bio Hub. We were thrilled to welcome Jaideep Dudani, Founding CEO of Ouro Medicines and Portfolio Principal at Monograph Capital. Jaideep holds a PhD from MIT and a BS in Bioengineering from UCLA. Jaideep began his career at Vida Ventures and played key R&D, strategy, and business development roles at Relay Therapeutics. Jaideep later helped launch Human Immunology Biosciences (HI Bio), leading portfolio development and strategic initiatives prior to its acquisition by Biogen.In early 2025, he co founded Ouro Medicines—backed by Monograph, GSK, NEA, TPG, Norwest, and others to pull of an incredible $120M Series A, to pioneer ‘immune reset’ T cell engager therapies targeting B cell mediated autoimmune and inflammatory diseases. We’ll explore Jaideep's journey from bioengineering research to biotech entrepreneurship, as well as the promising data from Ouro Medicines as well as Jaideep’s experience with building biotechs out from the ground up. Lees meer
-
Episode 56– Alec Ford & Stacy Solorio - CEO and Chief People Officer at Karius
18 juli 2025 · 36 min
So welcome back to another episode of the Bio Hub, we were delighted to welcome Alec Ford (CEO of Karius) and Stacy Solorio (Chief people Officer at Karius). Alec is a veteran of the genomics and biotech industries with over 30 years of leadership experience. Alec is leading the charge in transforming infectious disease diagnostics through Karius’s groundbreaking liquid biopsy test, which uses microbial cell-free DNA and AI to detect over 1,000 pathogens from a single blood draw. Before joining Karius, Alec served as COO at Myriad Genetics, where he scaled diagnostics across oncology, women’s health, and prenatal care, and held senior roles at Pfizer, Novartis, Sanofi, and Nektar. His leadership is deeply informed by personal experience—his family’s encounter with severe infections underscored the critical need for faster, more precise diagnostics.Stacy Solorio is the Chief People officer at Karius. Stacy is a strategic people leader with deep expertise in building culture and scaling teams within fast-growing biotech organizations. She’s also the founder of Biocom’s HR Biotech Group and Executive HR Education program, and serves on the board of the Biocom California Institute. At Karius, she’s helping align talent initiatives with the company’s mission to bring cutting-edge diagnostics into clinical practice. Lees meer
-
Episode 55– Dr Dan Williams - CEO SynaptixBio
10 juli 2025 · 33 min
We were delighted to welcome Dr. Dan Williams, CEO and co-founder of SynaptixBio, a pioneering biotech company on a mission to develop life-changing treatments for children affected by devastating brain disorders, onto the bio hub. With over two decades of experience in the biotech and pharmaceutical industries, Dan has led teams from the lab bench to global clinical programs, and now he’s tackling one of the rarest and most challenging neurological diseases: TUBB4A-related leukodystrophies, including the severe H-ABC form.Under Dan’s leadership, SynaptixBio is leveraging cutting-edge antisense oligonucleotide (ASO) technology to silence disease-causing genes and bring hope to families with no existing treatment options. In just a few years, his team has secured orphan drug designations, raised significant funding, and is driving toward clinical trials with an urgency that reflects the needs of the patients they serve.We’ll talk to Dan about his journey from scientist to biotech CEO, the science behind SynaptixBio’s approach, and what it takes to bring a rare disease therapy from concept to clinic. Lees meer
-
Episode 54– Adam Thomas - Chief People and Experience officer at Moma Therapeutics
9 juli 2025 · 28 min
We were delighted to welcome Adam Thomas, Chief People & Experience Officer at MOMA Therapeutics onto the Bio Hub, where he brings over two decades of strategic HR leadership across the biotech, pharmaceutical, and consumer industries. Since joining MOMA in 2024, Adam has led the company’s people and culture strategy during its pivotal transition into a clinical-stage organization, focusing on creating a world-class employee experience that integrates physical, digital, and cultural environments. Prior to MOMA, he served as Chief People Officer and Corporate Secretary at Synlogic, Inc., where he guided HR and talent strategy through the company’s growth from pre-clinical to Phase III development. He also held senior HR leadership roles at Shire Pharmaceuticals, where he oversaw HR for Research & Development during a major expansion, and at SC Johnson, leading HR for Research, Development & Engineering with an emphasis on talent development and organizational effectiveness. Earlier in his career, Adam spent over a decade at Pfizer in a variety of HR leadership roles and held advisory and research roles at Gartner (formerly CEB) and Brann Worldwide. He holds an LL.B. in Law from the University of Edinburgh, an M.A. in Human Resource Management from the University of the West of England, and an M.B.A. from Boston University Lees meer
-
Eamonn Hobbs- Founder, President & CEO of Syncromune at BIO Boston 2025
8 juli 2025 · 9 min
From BIO Boston: Eamonn Hobbs, CEO of Syncromune Lees meer
Eamonn Hobbs is a biotech veteran and serial CEO — and in this episode, he shares how Syncromune is rewriting the playbook for immunotherapy.
We talk about:
– How Syncromune’s SYNC-T platform delivered 87% ORR and 53% CR in mCRPC– What it means to synchronize drug, device, and immune response– Raising one of the few $100M Series A rounds in 2024– The mindset needed to build and win in today’s brutal marketEamonn’s clarity, experience, and grit shine through — this is a must-listen for anyone building in biotech.
More BIO Boston episodes dropping soon.
-
Spike Lo - VP Business Development of AP Bio at BIO Boston 2025
8 juli 2025 · 7 min
From BIO Boston: Spike Lo, VP of Business Development at AP Biosciences Lees meer
In this episode, I sit down with Spike Lo — a seasoned BD leader helping take AP Biosciences global.
We dive into:
— The rise of AP and their $96M raised to date— How their CD137-based T-cell engager platform is built for safety and precision— What sets Taiwan’s biotech ecosystem apart— Spike’s mindset on resilience, urgency, and global partnershipsA sharp conversation on building cross-border biotech with bold ambition.
This episode is part of our in-person series from BIO 2025 — more to come.
-
Josh Mandel-Brehm - CEO CAMP4 Therapeutics at BIO Boston 2025
7 juli 2025 · 12 min
Josh Mandel-Brehm, CEO of CAMP4 Therapeutics Lees meer
In this episode, I sit down with Josh Mandel-Brehm, the CEO of CAMP4 — a company pioneering a completely new approach in RNA therapeutics: upregulating gene expression using antisense oligonucleotides (ASOs).
Josh shares the journey from a 5-person team to a publicly traded company, and how CAMP4’s platform is unlocking treatment for diseases previously out of reach — particularly in rare genetic and CNS disorders.
We dive into:
— What makes CAMP4’s approach so different— How they’ve scaled in a challenging market— The transition from private to public— Building culture through rapid growth— What’s coming next in Syngap, urea cycle disorders, and moreJosh is sharp, mission-driven, and speaks with clarity on how to build a resilient biotech from the ground up.
This is one for anyone building bold platforms in biotech.
-
Jan Thirkettle - CEO Harness Therapeutics at BIO Boston 2025
7 juli 2025 · 8 min
From BIO Boston: Jan Thirkettle, CEO of Harness Therapeutics Lees meer
In this episode, I sit down with Jan Thirkettle, a biotech leader with deep experience across gene therapy, platform innovation, and company-building.
Jan was part of the team that helped bring one of the first ex vivo gene therapies to market. Today, he’s leading Harness Therapeutics — a UK-based company developing a novel class of RNA therapeutics (MISBA tech) to upregulate protein expression with unprecedented precision.
We talk about:— Why Harness is targeting neurodegeneration and CNS— The company’s unique approach to hitting “unprosecuted” targets— Building a biotech from scratch — and doing it in the UK— What he's learned about culture, resilience, and scaling teams
This is a sharp, grounded chat with a leader who’s genuinely passionate about building great science and great teams.
More in-person interviews from BIO Boston to follow.
-
Adam Mendelsohn - CEO & Co-Founder Vivani Medical at BIO Boston 2025
7 juli 2025 · 10 min
From BIO Boston: Adam Mendelsohn, CEO of Vivani Medical Lees meer
In this episode, I sit down with Adam Mendelsohn — bioengineer turned biotech CEO — and the co-founder of Vivani Medical.
What started in a university basement has grown into a publicly listed company tackling one of the biggest challenges in healthcare: medication adherence.
We talk about:
— Building a biotech from scratch, and staying alive in tough times— Why GLP-1 implants could transform obesity and diabetes care— The mindset behind navigating clinical milestones and setbacks— And how Vivani’s platform could reshape drug delivery entirelyAdam’s story is full of grit, clarity, and ambition — and Vivani is just getting started.
This episode is part of a series of in-person interviews from BIO Boston with some of the sharpest leaders in the industry.
More to come.
-
Steve Butts - CEO Arrivo Bio at BIO Boston 2025
2 juli 2025 · 10 min
From BIO Boston: Steve Butts, CEO of Arrivo BioVentures Lees meer
In this episode, I sit down with Steve Butts — a five-time biotech founder and the CEO of Arrivo BioVentures.
Steve has built and exited multiple companies, and now he's applying everything he’s learned to build Arrivo with precision: lean, capital-efficient, and structured for smart growth.
We talk about:
— How to build programs that big pharma wants— Why Arrivo structures its assets in separate subsidiaries
— Navigating the current market as a small, focused team
— And the mindset it takes to keep building in tough conditions
Steve’s approach is clear, disciplined, and proven - this is biotech company-building done right.
This episode is part of a series of in-person interviews from BIO Boston with some of the sharpest leaders in the industry.
More to come.
-
The BioHub - Avetix Podcast - S2 Ep53 - Lisa DiPaolo - Chief Human Resources Officer at Karyopharm
26 juni 2025 · 21 min
Lisa DiPaolo is the Executive Vice President and Chief Human Resources Officer at Karyopharm Therapeutics, where she brings over two decades of HR leadership in the pharmaceutical and biotech industries. Since joining Karyopharm in September 2022, she has led the company’s People & Culture strategy through a critical period of growth and transformation. Before this, Lisa served as SVP of HR at Ipsen, overseeing North America as well as global R&D and Business Development, where she drove significant organizational and cultural shifts. She also spent eight years at Biogen in a series of senior roles, including leadership of global therapeutic operations, executive search, and medical affairs HR. Her earlier career included HR leadership roles at Smiths Medical and nearly a decade at Novartis, managing both U.S. and global teams. Lisa holds a B.A. from Montclair State University and an M.S. in Human Resource Management from Rutgers University. Known for her focus on authentic leadership, culture-driven transformation, and scalable HR systems, she is passionate about creating resilient, people-centric organizations that align business goals with strong employee experience. Lees meer
-
Episode 52– Aaron Royston - Managing Partner at VenBio
5 juni 2025 · 27 min
Dr. Aaron Royston, M.D., M.B.A., is a Managing Partner at venBio, a life sciences venture capital firm, where he brings over 15 years of experience in biotechnology investing, company formation, and clinical research. His leadership has contributed to the launch and growth of several successful biotech companies, including Apellis Pharmaceuticals, Ventyx Biosciences, Akero Therapeutics, Harmony Biosciences, and RayzeBio, collectively achieving multiple FDA drug approvals. Before joining venBio, Dr. Royston was part of the investment team at Vivo Capital and worked at Bain & Company, advising biotechnology firms on strategic and operational matters. He began his career coordinating clinical research at Mount Sinai Medical Center, with his work published in various medical journals. Dr. Royston holds a B.S. in Biological Sciences from Duke University and earned both his M.D. and M.B.A. from the University of Pennsylvania. As a student, he founded a technology company that was later acquired, earning him recognition from the White House in 2010 as a Champion of Change for his contributions to technology and innovation. In addition to his role at venBio, Dr. Royston serves on the boards of multiple biotech companies, including Candid Therapeutics, Attovia Therapeutics, 35 Pharma, and ViceBio. Lees meer
-
Episode 51 – Harith Rajagopalan - CEO & CO-Founder Fractyl Health
3 juni 2025 · 21 min
Dr. Harith Rajagopalan is the Co-founder and CEO of Fractyl Health, a company he launched while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Before founding Fractyl, Dr. Rajagopalan was an academic cardiologist and physician-scientist. He earned his B.S. in Chemistry from Stanford University and obtained both M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, he conducted award-winning research on intestinal cancers, with findings published in leading journals such as Nature and Science. Following medical school, he completed his residency in internal medicine and fellowship in clinical cardiology at Brigham and Women’s Hospital, along with a research fellowship at the Harvard Stem Cell Institute. Under Dr. Rajagopalan's leadership, Fractyl Health has developed innovative therapies targeting metabolic diseases. Notably, the company is advancing Rejuva®, a gene therapy platform designed for long-term remission of obesity and type 2 diabetes by altering metabolic hormone function in pancreatic islet cells. Rejuva is expected to enter first-in-human studies in the first half of 2025. Lees meer
-
Episode 50 – Marc de Garidel & Sylvie Grégoire – CEO & Chair of Abivax
27 mei 2025 · 34 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
In this special follow-up episode, I’m rejoined by Marc de Garidel, CEO of Abivax, after our hugely popular conversation last year—recorded just after their record-breaking NASDAQ IPO. That episode gave us a look into Marc’s incredible career, the company’s bold vision, and how they were gearing up to become a major player in inflammatory diseases.
This time, he’s joined by Sylvie Grégoire, Chair of the Abivax Board—a hugely respected industry leader with decades of global biotech and pharma experience.
Together, we dive into what’s changed in the past year, how they’re navigating today’s biotech climate, and what’s next for Abivax as they continue to push forward in ulcerative colitis and beyond.
Two powerhouse leaders. One big conversation.
Enjoy and stay tuned.
-
Episode 49 - Lisa Deschamps- CEO of Aviadobio
20 mei 2025 · 29 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Lisa Deschamps, CEO of AviadoBio.
After 25 years at Novartis, leading global launches in gene therapy, she’s now at the helm of AviadoBio—developing treatments for FTD and ALS.
We talk career moves, mindset, culture, and what’s ahead.
Enjoy and stay tuned.
-
Episode 48 - Michael Kauffman- CEO of Nereid Therapeutics
15 mei 2025 · 31 min
We're honored to have Dr. Michael Kauffman, M.D., Ph.D., the Chief Executive Officer of Nereid Therapeutics, joining us.Dr. Kauffman brings over 25 years of experience in the life sciences industry, with a distinguished track record in oncology drug development. Currently, he leads Nereid Therapeutics, a company at the forefront of pioneering therapies targeting biomolecular condensates—a novel approach to treating complex diseases. Under his leadership, Nereid is advancing multiple programs in oncology and neurodegeneration toward clinical application. PR NewswirePrior to his role at Nereid, Dr. Kauffman co-founded Karyopharm Therapeutics, where he served as CEO and guided the company from discovery to the global approval of XPOVIO® for multiple myeloma and non-Hodgkin’s lymphoma. His extensive experience also includes leadership positions at Onyx Pharmaceuticals, Millennium Pharmaceuticals, and Biogen. Dr. Kauffman earned his M.D. and Ph.D. from Johns Hopkins Medical School and completed his training in Internal Medicine at Beth Israel Deaconess Medical Center and in Rheumatology at Massachusetts General Hospital. He is board-certified in Internal Medicine and licensed in Massachusetts and Florida. In this episode, we'll delve into Dr. Kauffman's journey in the biotech industry, the innovative science behind Nereid's approach, and the future of targeted therapies in treating complex diseases. Lees meer
-
Episode 47 - Julie Person
1 mei 2025 · 24 min
We were delighted to be joined by Julie Person on the BioHub podcast, an accomplished human resources and organizational leader with over 20 years of experience in the biopharmaceutical industry. She currently serves as Chief Administrative Officer at Third Harmonic Bio, where she leads company operations, including human resources, communications, and organizational strategy.Julie has a strong track record of helping biotech companies scale and thrive through critical growth stages. Prior to her current role, she was Chief People Officer at Neumora Therapeutics, and held senior HR leadership positions at Sangamo Therapeutics, Audentes Therapeutics, Shire, and Baxalta. Her expertise lies in building high-performing teams, shaping company culture, and aligning talent strategies with business goals.She holds a degree from Saint Mary's College of California and completed an Executive Leadership Program at the University of Michigan Ross School of Business. Lees meer
-
Episode 46 - Alexander Zehnder - CEO of Curevac
30 april 2025 · 29 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Alexander Zehnder, CEO of CureVac — a company that’s been pioneering mRNA technology for 25 years.
Alexander stepped into the CEO role in 2023 and has been leading CureVac through a critical transformation: securing a €1.45 billion partnership with GSK, executing a strategic pivot, and driving a major cultural shift within the organization. With a background in medicine and a career spanning Roche, Genentech, and Sanofi, he brings a unique perspective on what it takes to lead at scale while staying patient-focused.
We dive into the evolution of mRNA, the story behind CureVac’s next chapter, and the mindset needed to lead through change.
Enjoy and stay tuned.
-
Episode 45 - Dr. Claudia Zylberberg - Founder of Akron Biotech
17 april 2025 · 35 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Dr. Claudia Zylberberg — a pioneering force in cell and gene therapy and the founder of Akron Biotech.
Claudia has spent her career shaping the future of biologics manufacturing, building Akron into a key player in the CGT ecosystem, and championing the development of global standards for advanced therapies. She’s a scientist, an entrepreneur, and an advocate for innovation, quality, and access in one of the most complex areas of biotech.
From founding startups to influencing international policy, Claudia brings a wealth of experience and insight to the table — and I can’t wait to get into it.
Enjoy and stay tuned.
-
Episode 44 - Uwe Schoenbeck, Partner of Canaan
9 april 2025 · 29 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
On this episode of The BioHub, I’m joined by Uwe Schoenbeck, Partner at Canaan and one of the most respected names in early-stage biotech.
After more than a decade leading external science and innovation at Pfizer, Uwe made the jump to venture capital, joining Canaan in 2023. With a background spanning big pharma, startups, and science itself—he’s uniquely positioned to see what’s coming next.
In this episode, we talk about the shift from pharma to VC, what founders get wrong when pitching, and the traits that separate the good companies from the great ones.
Enjoy and stay tuned.
-
JP Morgan David Happel
3 april 2025 · 8 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have David Happel, CEO of Sagimet Biosciences
Listen to hear how they've been doing.
-
Episode 43 - Gwen Acton, Vivo Group
2 april 2025 · 34 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Gwen Acton, CEO of Vivo Group and an expert in leadership development for scientists, engineers, and biotech professionals.
Gwen has had a fascinating career—she earned a PhD from MIT, was a faculty member at Harvard, ran operations at the Whitehead Institute during the Human Genome Project, and has helped thousands of technical experts become stronger leaders.
Now, she’s adding “author” to her resume with a brand-new book on leadership, and today, we’re diving into why leadership is so crucial in biotech, how it’s evolved, and what inspired her to write it.
Enjoy and stay tuned
-
Episode 42 - David De Graaf, CEO of Reverb Therapeutics
2 april 2025 · 27 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Today we're joined by David De Graaf, CEO of Co-Founder of Reverb TherapeuticsDavid has an incredible background, with positions at companies such as AstraZeneca, Pfizer, Apple Tree Partners & Boehringer Ingelheim as well being at the helm of multiple successful biotechs. In this episode, we dive into his journey, building out seed stage biotech's from scratch as well as the Canadian Biotech scene Lees meer
-
Episode 41 - Judy Chou, CEO of Altrubio
19 maart 2025 · 35 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Judy Chou, CEO of AltruBio—one of the mostexciting biotech companies out there, especially after closing the largest Series B in biotech over the last four years.
Judy has an incredible background, having led global biotechat Bayer, held leadership roles at Pfizer, and served as research faculty at Harvard. Now, as the CEO of AltruBio, she’s driving the company’s mission to develop first-in-class immune modulators for autoimmune and inflammatorydiseases.
In this episode, we dive into her journey, how AltruBio isthriving in a tough market, and what’s ahead for the company in 2024. Let’s get into it!
Enjoy and stay Tuned.
-
Episode 40 - Aoife Brennan, CEO of Climb Bio
12 maart 2025 · 33 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Aoife Brennan, CEO of Climb Bio—a company at the cutting edge of pioneering new approaches to cell and gene therapy.
Aoife is a seasoned biotech leader with a track record of driving innovation. Before joining Climb Bio, she was the CEO of Synlogic, where she led the company through critical clinical advancements in engineered probiotic medicines.
With a background in medicine and deep experience in biotech strategy, she has a unique perspective on bridging science and business to create transformative therapies.
In this episode, we talk about her journey, what makes Climb Bio’s approach different, and how she’s navigating leadership in an ever-evolving industry.
Enjoy and stay Tuned.
-
Episode 39 - Shalabh Gupta, CEO of Unicycive
5 maart 2025 · 20 min
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Shalabh Gupta, a seasoned leader in the biotech industry and the current Founder, Chairman & CEO of Unicycive Therapeutics. Shalabh's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of Globavir Biosciences and CEO, Founder, Chairman and of BioCycive.Now, at the helm of Unicycive Therapeutics, Unicycive who are focused on developing new treatment options for patients with renal diseases, as kidney disease remains a major global health concer. Lees meer
-
Episode 38 - Iain Kilty, CEO of Sitryx
5 maart 2025 · 35 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Iain Kilty, CEO of Sitryx, a biotech pushing boundaries in immunology and inflammation.
Iain’s journey is fascinating—after 22 years at Pfizer, leading global drug discovery efforts, he transitioned into biotech, taking on the CSO role at Sitryx before stepping up as CEO. Now, he’s leading the charge as Sitryx enters the clinic, a huge milestone for any company.
In this episode, we dive into:
The science behind Sitryx’s breakthrough work
The UK biotech scene vs. the US—fundraising, growth, and challenges
What’s next for Sitryx as they push toward transforming patient care
Enjoy and stay Tuned.
-
Episode 37 - John Mumm, CEO & Co-Founder of Deka Biosciences
25 februari 2025 · 31 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by John Mumm, CEO of Deka Biosciences—a company breaking new ground in cytokine therapies for cancer and inflammatory diseases.
John is a true veteran of biotech, with over 30 years of experience in immunotherapy research. He’s spent his career working to unlock the potential of IL-10 and cytokines, tackling one of drug development’s biggest challenges. After leadership roles at MedImmune, and ARMO BioSciences, he founded Deka to bring a fresh approach to cytokine-based treatments.
Today, we dive into John’s journey as a three-time biotech founder, the fast-moving progress at Deka, and why cytokines have been so tough to crack—until now. Plus, we get into mindset, motivation, and what it takes to build a company that lasts.
Enjoy and Stay Tuned.
-
Episode 36 - Melissa Sherman, CEO of MOBILion Systems
19 februari 2025 · 26 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Melissa Sherman, CEO of MOBILion Systems—a true trailblazer shaking up separation science.Melissa was employee number one and has since raised $120M, built a world-class team, and launched Mobi, a technology that’s transforming how we analyze molecules. Think of it like upgrading from an old film camera to the latest high-definition digital—faster, clearer, and game-changing for drug developers.We dive into her inspiring journey of building MOBILion from the ground up, creating a winning company culture, and why she believes this tech is the future of separation science.Enjoy and Stay Tuned. Lees meer
-
JP Morgan Stella Vnook
13 februari 2025 · 6 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Stella Vnook, CEO of Likarda.
Listen to hear how they've been doing.
-
JP Morgan Patrick Alexandre
11 februari 2025 · 12 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Patrick Alexandre, CEO of Crossject.
Listen to hear how they've been doing.
-
Episode 35 - David Esposito, CEO ONL Therapeutics
11 februari 2025 · 23 min
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David Esposito, a seasoned leader in the biotech industry and the CEO of ONL Therapeutics. David's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as President and CEO of Armune Biosciences, VP Commercial Operations at Thermo Fisher, and Executive Director Commercial Strategy at Merck. Lees meer
-
JP Morgan Glen Gowers
11 februari 2025 · 5 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Glen Gowers, CEO and co-Founder of Basecamp Research.
Listen to hear how they've been doing.
-
JP Morgan Simrit Parmar
11 februari 2025 · 16 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Simrit Parmar, Founder of Cellenkos.
Listen to hear how they've been doing.
-
JP Morgan Angelos Stergiou
11 februari 2025 · 16 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Angelos Stergiou, CEO of Sellas Life Sciences
Listen to hear how they've been doing.
-
JP Morgan Michael Parini
11 februari 2025 · 7 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Michael Parini, CEO of Spur Therapeutics.
Listen to hear how they've been doing.
-
JP Morgan Yang Liu
11 februari 2025 · 6 min
Our little spin off of our time at JPM! Lees meer
Big announcements and exclusives! Here we have Yang Liu, CEO & CSO of OncoC4.
Listen to hear how they've been doing.
-
JP Morgan Adrian Rawcliffe
11 februari 2025 · 15 min
The first of our little spin off and time at JPM! Lees meer
Big announcements and exclusives! Here we have Adrian Rawcliffe, CEO of Adaptimmune.
Listen to hear how they've been doing.
-
Episode 34 - Michael Castagna, CEO Mannkind
11 februari 2025 · 36 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We have a special guest—Michael Castagna, CEO of MannKind Corporation. Michael has over 25 years of experience in marketing, sales, and business development across both Fortune 500 companies and biotech startups.
Under his leadership, MannKind has grown into a major player in the field of endocrine and orphan lung diseases, bringing innovative therapies like Afrezza®, the only inhaled ultra-rapid-acting insulin, to market.
In this episode, Michael shares his journey, the challenges and triumphs of leading MannKind, and the future of the company’s groundbreaking technologies.
We also dive deep into his passion for turning around struggling companies and the lessons he’s learned from navigating the biotech landscape.
Enjoy and Stay Tuned.
-
Episode 17 - Kevin Warner, SVP Heron Therapeutics
7 februari 2025 · 34 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We are thrilled to welcome Dr. Kevin Warner, Senior Vice President of Medical Affairs strategy and engagement at Heron Therapeutics.
Dr. Warner brings 2 decades of experience in clinical and infusion pharmacy, with a special focus on pharmacokinetics, pharmacodynamics, and antimicrobial stewardship. He has been instrumental in co-developing the VT-X7 intra-articular antibiotic irrigation therapy and has played a crucial role in numerous committees dedicated to improving patient care.
At Heron Therapeutics, Dr. Warner is at the forefront of enhancing recovery after surgery and developing innovative pharmaceutical products using their proprietary Biochronomer™ drug delivery platform. With his extensive background and dedication to advancing patient care, Dr. Warner is a true leader in the pharmaceutical industry.
We’re excited to dive into his journey, explore Heron’s
groundbreaking work, and discuss the future of pharmaceutical innovation.Enjoy and stay tuned.
-
Episode 33 - Mark Mallon, CEO George Medicines
5 februari 2025 · 33 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We have Mark Mallon, CEO of George Medicines. Lees meerMark is a global leader in the pharmaceutical industry with over 25 years of experience. His career includes 24 years at AstraZeneca, where he held several key executive positions, leading operations across the globe.
More recently, Mark has served as the CEO of NeoGenomics Laboratories and Ironwood Pharmaceuticals, driving transformation and growth in both roles. Now at George Medicines, Mark leads the development of innovative, combination therapies designed to optimize the treatment of cardiometabolic diseases.
In this episode, we’ll explore Mark’s journey to George Medicines, the company’s innovative approach to tackling cardiometabolic diseases, and the importance of addressing global health inequities.
Welcome to the show, Mark! Enjoy and stay tuned.
-
Episode 32 - Sam Clark, Founder and CEO of Terran Biosciences
17 januari 2025 · 18 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We are joined today by Founder and CEO of Terran Biosciences. Sam is a trailblazer in the Neuroscience space.
We discuss a number of topics in this episode but have a lot of focus on recent FDA breakthroughs, upcoming plans with their lead drug TerXT.
-
Episode 31 - Jason Bock, Founder and CEO of CTMC
10 januari 2025 · 37 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We're joined by CEO and Founder, Jason Bock. Jason has been instrumental in the mAb space, and now making a move into the CAR-T space.
In this episode, Jason shares his career experience, the move from mAb to CAR-T, and how CTMC is playing their part in this.
-
Episode 30 - Joe Payne, Founder, President & CEO of Arcturus Therapeutics
8 januari 2025 · 32 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We’re joined by Joe Payne, CEO and founder of Arcturus Therapeutics. Joe has been instrumental in pushing the boundaries of mRNA technology, leading Arcturus to develop one of the first self-amplifying mRNA COVID-19 vaccines and pioneering new treatments for diseases like cystic fibrosis.
In this episode, Joe shares his journey, the ground breaking work at Arcturus, and his vision for the future of RNA medicine.
Let’s dive in!
Enjoy and stay tuned.
-
Episode 29 - Adrian Rawcliffe, CEO of Adaptimmune
18 december 2024 · 45 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m pleased to introduce Adrian Rawcliffe, CEO of Adaptimmune Therapeutics. With over 20 years of experience in the pharmaceutical and biotech industries, Adrian has led pivotal roles at GSK and now spearheads the development of breakthrough T-cell therapies at Adaptimmune, tackling some of the toughest challenges in cancer and beyond.
We’re excited to dive into Adrian’s journey, the advancements at Adaptimmune, and what the future holds for T-cell therapies. Welcome to the show, Adrian!
Enjoy and stay tuned.
-
Episode 28 - Greg Kunst, CEO of Aurion Biotech
10 december 2024 · 35 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We have the pleasure of hosting Greg Kunst, CEO of Aurion Biotech. Greg is a seasoned leader in the biotech industry with a remarkable career spanning drug development, commercialization, and market access.
At Aurion, Greg has driven the company to incredible heights, raising over $200 million and securing product approval in Japan for their groundbreaking cell therapy platform. Under his leadership, Aurion has grown rapidly, with operations expanding across the U.S. and Japan.
In this episode, we’ll explore Greg’s journey from his extensive experience in the industry to taking the helm at Aurion, the innovative technologies driving their mission, and what the future holds for this cutting-edge biotech company.
Enjoy and stay tuned.
-
Episode 27 - Sophia Lugo, CEO of Radar Therapeutics
20 november 2024 · 44 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. Lees meer
We’re thrilled to have Sophia Lugo, CEO and co-founder of Radar Therapeutics. Sophia’s journey from El Paso to leading Radar is truly inspiring. Her passion for medicine and public health drives her mission to bring representation and accessibility to mRNA therapies.
Radar Therapeutics is pioneering precision-expressed mRNAs to target specific diseased cells, aiming to revolutionize treatments for conditions like cancer and rare diseases. Recently, Radar raised $13.4 million in seed funding to advance their groundbreaking work.
In this episode, we’ll explore Sophia’s journey, the technology behind Radar, and the importance of health equity in medicine.
Enjoy and stay tuned.
-
Episode 26 - David-Alexandre "DA" Gros, CEO & Director of Eledon Pharmaceuticals
18 november 2024 · 30 min
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David-Alexandre "DA" Gros, a seasoned leader in the biotech industry and the current CEO & Director of Eledon Pharmaceuticals. DA's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO Imbria Pharmaceuticals, President and Chief Operating Officer of Neurocrine Biosciences, Chief Business and Principal Financial Officer at Alynlam Pharmaceuticals, Chief Strategy Officer and EVP, Strategy & Business Development at Sanofi, Principal, Healthcare Investment Banking at Centerview Partners & Vice President, Healthcare Investment Banking at Merrill Lynch. Lees meer
Now, at the helm of Eledon Pharmaceuticals, Eledon are focused on striving to both extend the functional life of transplanted organs and reduce side effects of current immunosuppressive treatments such as kidney toxicity, high blood pressure, and tremor.
DA's deep expertise, from startups to larger pharmaceutical companies gives him a unique perspective on how to steer innovative science towards tangible clinical outcomes. We're excited to dive into his journey, the challenges and successes along the way, changing career lanes & the business development landscape.
-
Episode 25 - Charmaine Lykins, Commercial Strategy
14 november 2024 · 33 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.We are thrilled to have Charmaine Lykins, Commercial Strategy Advisor at MapLight Therapeutics, join us. Lees meer
Charmaine brings over 25 years of extensive experience in the commercial sector of psychiatry and neurology. Prior to MapLight, she was the Commercial Strategy Advisor at Karuna Therapeutics, where she spearheaded the commercial capabilities for the launch of KarXT in schizophrenia and Alzheimer's disease psychosis.
Charmaine's impressive career includes commercial strategy and execution for 10 product launches in the US and globally for CNS indications.
In this episode, we’ll dive into the resurgence of interest in neuro and CNS disorders, the importance of involving commercial teams early in development, and the challenges and rewards of bringing new treatments to market.
Enjoy and stay tuned